Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more
Futura Medical (FUM) - Total Liabilities
Latest total liabilities as of June 2025: GBX2.44 Million GBX
Based on the latest financial reports, Futura Medical (FUM) has total liabilities worth GBX2.44 Million GBX as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Futura Medical - Total Liabilities Trend (2001–2024)
This chart illustrates how Futura Medical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Futura Medical Competitors by Total Liabilities
The table below lists competitors of Futura Medical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VietNam Holding Limited
LSE:VNH
|
UK | GBX178.61K |
|
Premier Exhibitions Inc
PINK:PRXIQ
|
USA | $32.21 Million |
|
Macau Property Opportunities Fund Ltd
LSE:MPO
|
UK | GBX47.78 Million |
|
Pacific Assets Trust plc
LSE:PAC
|
UK | GBX12.05 Million |
|
China Food and Beverage Company
PINK:CHIF
|
USA | $63.82 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Futura Medical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Futura Medical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Futura Medical (2001–2024)
The table below shows the annual total liabilities of Futura Medical from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX4.63 Million | -27.01% |
| 2023-12-31 | GBX6.34 Million | +261.62% |
| 2022-12-31 | GBX1.75 Million | -15.64% |
| 2021-12-31 | GBX2.08 Million | +171.12% |
| 2020-12-31 | GBX766.52K | -84.19% |
| 2019-12-31 | GBX4.85 Million | +139.32% |
| 2018-12-31 | GBX2.03 Million | +305.80% |
| 2017-12-31 | GBX499.14K | -41.63% |
| 2016-12-31 | GBX855.18K | +17.29% |
| 2015-12-31 | GBX729.12K | +19.94% |
| 2014-12-31 | GBX607.89K | +27.17% |
| 2013-12-31 | GBX478.00K | +42.71% |
| 2012-12-31 | GBX334.95K | +72.66% |
| 2011-12-31 | GBX194.00K | +27.63% |
| 2010-12-31 | GBX152.00K | -32.14% |
| 2009-12-31 | GBX224.00K | +47.37% |
| 2008-12-31 | GBX152.00K | -51.75% |
| 2007-12-31 | GBX315.00K | +33.47% |
| 2006-12-31 | GBX236.00K | -0.42% |
| 2005-12-31 | GBX237.00K | +5.33% |
| 2004-12-31 | GBX225.00K | +25.00% |
| 2003-12-31 | GBX180.00K | -27.13% |
| 2003-01-31 | GBX247.00K | -5.73% |
| 2002-01-31 | GBX262.00K | -58.41% |
| 2001-01-31 | GBX630.00K | -- |